Objective:To evaluate the efficacy of Lanqin oral liquid combined with Azithromycin in treating mycoplasma pneumoniae pneumonia children with syndrome of heat-toxicity blocking lung. Methods:A total of 82 children with mycoplasma pneumoniae from January of 2017 to January of 2019 who met the inclusion criteria were divided into two groups according to the random number table method with 41 patients in each group. The control group was given with Azithromycin sequential therapy, and the observation group was given with Lanqin oral liquid on the basis of conventional western medicine. Both groups were treated for 7 days. Scores of symptoms and signs were evaluated before and after treatment, serum levels of IL-4 and tumor necrosis TNF-α were detected by ELISA method, the disappearance time of fever, cough, dry and wet ralogue and wheezing were observed and recored, adverse reactions occurred during treatment were recorded, and the clinical efficacy was evaluated. Results:The total effective rate of the observation group and the control group was 95.1% (39/41) and 75.6% (31/41), respectively, and the difference was statistically significant ( χ2=4.783, P=0.029). The antipyretic time, cough disappearance time, dry and wet ralogue disappearance time, and wheezing disappearance time of the observation group were significantly shorter than those of the control group ( t=9.312, 8.740, 7.350, 12.467, respectively, all Ps<0.001). After treatment, the scores of cough, fever, wheezing, thirst, phlegm yellow thick and difficultly coughing in the observation group were significantly lower than those in the control group ( t=14.350, 16.779, 18.005, 17.441, 23.633, respectively, all Ps<0.001). After treatment, the scores of cough, fever, wheezing, thirst, yellow thick phlegm and difficultly in coughing in the observation group were significantly lower than those in the control group ( t=14.350, 16.779, 18.005, 17.441, 23.633, respectively, all Ps<0.001). After treatment, serum levels of IL-4 (12.56 ± 1.80 ng/L vs. 17.09 ± 2.78 ng/L, t=8.758) and TNF-α (14.08 ± 2.15 ng/L vs. 20.04 ± 2.93 ng/L, t=10.501) of the observation group were significantly lower than those of the control group ( P<0.01). The incidence of adverse reactions in the control group and the observation group was 17.07% (7/41) and 19.51% (8/41) respectively, and the difference was not statistically significant ( P>0.05). Conclusions:Lanqin oral liquid combined with Azithromycin can improve symptoms of mycoplasma pneumoniae pneumonia children and down-regulate serum levels of IL-6 and TNF-α, increase the efficacy with safety.